| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8fb1456312aa7998c552f43f015e6bc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 |
| filingDate |
2018-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11b003259158a96398445d8ea25edf83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_127d6ddaed1c09a20ebbf6f430c3e6ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b9e4cea5ba022ec74e1ca72bac55716
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db7f2c30cd8cd68654a3106d666a5bad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f18ea6779438f64881a2f721ebf332a |
| publicationDate |
2021-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11059813-B2 |
| titleOfInvention |
Polymorphic forms of Dasatinib |
| abstract |
The present invention provides for the dasatinib-thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±)-1, 2-Butanediol, crystalline dasatinib (R)-1, 2-Butanediol, crystalline dasatinib (S)-1, 2-Butanediol and crystalline dasatinib (±)-2, 3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib-butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib. The present invention also provides for a process for preparation of dasatinib monohydrate from anhydrous dasatinib. |
| priorityDate |
2017-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |